about
Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementiaA 3-month-old baby with H1N1 and Guillain-Barré syndrome.Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS).Awaji criteria improves the diagnostic sensitivity in amyotrophic lateral sclerosis: A systematic review using individual patient data.Neurologic complications of craniovertebral dislocation.Proteomic analysis of plasma from Portuguese patients with familial amyotrophic lateral sclerosis.Roles of vascular endothelial growth factor in amyotrophic lateral sclerosis.A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories.Neurophysiological techniques to detect early small-fiber dysfunction in transthyretin amyloid polyneuropathy.Ataxin-2 intermediate-length polyglutamine expansions in European ALS patientsThe Neurophysiological Index in ALS.Influence of medical audit on electrodiagnostic evaluation of polyneuropathy. A multicentre study.Quality Control of Motor Unit Number Index (MUNIX) Measurements in 6 Muscles in a Single-Subject "Round-Robin" Setup.Controversies and priorities in amyotrophic lateral sclerosis.Pathophysiology inferred from electrodiagnostic nerve tests and classification of polyneuropathies. Suggested guidelines.Neurophysiological measures in amyotrophic lateral sclerosis: markers of progression in clinical trials.Pain and calf hypertrophy associated with spontaneous repetitive discharges treated with botulinum toxin.Clinical trials in ALS: a review of the role of clinical and neurophysiological measurements.Influence of peer review medical audit on pathophysiological interpretation of nerve conduction studies in polyneuropathies.Young-onset sporadic amyotrophic lateral sclerosis: a distinct nosological entity?Electrodiagnostic criteria for diagnosis of ALS.Electrophysiological studies in healthy subjects involving caffeine.Diagnosis, pathogenesis and therapeutic targets in amyotrophic lateral sclerosis.Amyotrophic lateral sclerosis: an update.EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force.Prognosis of phrenic nerve injury following thoracic interventions: four new cases and a review.Associated movement disorders in orthostatic tremor.Awaji criteria for the diagnosis of amyotrophic lateral sclerosis:a systematic review.Breathing new life into treatment advances for respiratory failure in amyotrophic lateral sclerosis patients.Motoneuron firing in amyotrophic lateral sclerosis (ALS)Integrative biomarker discovery in neurodegenerative diseases.Emerging molecular biomarker targets for amyotrophic lateral sclerosis.Lower motor neuron dysfunction in ALS.Sequence variations in C9orf72 downstream of the hexanucleotide repeat region and its effect on repeat-primed PCR interpretation: a large multinational screening study.Phosphoneurofilament heavy chain and N-glycomics from the cerebrospinal fluid in amyotrophic lateral sclerosis.Fasciculation in amyotrophic lateral sclerosis: origin and pathophysiological relevance.Sensitivity of MUP parameters in detecting change in early ALS.Orofacial apraxia in motor neuron disease.Clinical and neurophysiological evaluation of progression in amyotrophic lateral sclerosis.Implementation of a wireless device for real-time telemedical assistance of home-ventilated amyotrophic lateral sclerosis patients: a feasibility study.
P50
Q24323876-768C208D-26A7-4C5A-895D-A4269AE7EF8CQ30416899-B6E0ADF8-AD97-492E-BBA3-CF5044778585Q30836997-AAB53026-CA69-4613-97FD-29991C652D52Q31099553-C745AE91-7D33-4B27-A1DB-387E1614DCF7Q33163672-BAA5FD9E-E520-4FEE-9F58-38DE7A2FE786Q33349895-EEF67069-1F61-4A37-907D-42F455A50B6FQ33616384-B4B19476-BB8F-4E63-A074-315296B327F7Q33658563-A09A340E-4061-4078-AFC7-E8F6D38D40B7Q34726962-7F4A9DF9-ADC4-4347-9106-635CE314D0B8Q34766957-7F0AD715-5C83-4002-A123-197FBE6C92E6Q35932144-3A821595-8944-49C5-B4A0-24406680A755Q35979066-7D05E5E2-98E0-4191-8B93-EF6F82E88855Q36005072-86535065-7D64-4A77-8F7C-03FEBB53B547Q36045826-D6ECA90E-62C8-4722-9BBF-019CC10EBCEEQ36133991-DFBB6E2E-EEFC-460A-A9D2-CC5346DC6C1AQ36203600-2A6287FF-773D-4C43-A179-08D5550680DDQ36300300-8B940D6F-C7C0-48FF-8706-54D67E3B8ABDQ36327410-9BF91BCA-39A4-45E0-918C-7F1378633C6DQ36413538-A780F11C-B05C-447F-A4C3-240A508E1644Q36939384-592B5DC0-B286-4551-A381-37497DE29818Q37046933-CC7565FF-FAC5-4A07-A378-72C16EBD8C42Q37694177-8679E2DA-6DBD-4A16-9816-B6B351C1DD71Q37799848-A417D6FD-3101-4792-9378-1DAC84A58AA5Q37897117-234009AA-59B6-480A-A121-D3E44296C24BQ37931374-0E852AFC-5551-417C-8951-1384F21A87F6Q37973491-1BC39BC9-0E28-4FBC-8AAD-A5A4FF08B9E1Q38009299-3A1D2288-6626-44BC-8B0E-642F6DA6D0FDQ38034627-3580B0BD-5508-4306-AECF-4B76C9BE4A7EQ38196863-44B37FD4-3F5E-484D-B886-B185445C52CDQ38258073-ABB84AE1-6CEF-4384-ADE9-F2527AF7004DQ38542025-8A0810BD-96B8-4803-8BAC-0329B3BC289AQ38698955-945471D1-55C7-4E4B-8CD9-D0588364E6AEQ38818336-FFB86054-ABFB-4227-8634-97B7717BB02FQ39114204-28D775A5-457F-497B-9301-72D198751A47Q39122227-AF1B3D71-5127-4DAA-935A-1E54A44F3A7AQ39296498-A8C33B34-C70E-4AD4-ABCE-D440FA44F027Q39386422-829C732F-3976-4AAD-922D-C78EB5E64C26Q39635427-E9F8EC7F-6B95-4135-8B64-48D61C9FF5E9Q39667681-2F2F23B4-FDB5-4E1F-BF67-7F4CD6B42E38Q39830198-1E964156-56BB-4C87-8E81-4EF60E6F8668
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Mamede de Carvalho
@ast
Mamede de Carvalho
@en
Mamede de Carvalho
@es
Mamede de Carvalho
@nl
Mamede de Carvalho
@sl
type
label
Mamede de Carvalho
@ast
Mamede de Carvalho
@en
Mamede de Carvalho
@es
Mamede de Carvalho
@nl
Mamede de Carvalho
@sl
altLabel
Mamede Carvalho
@en
prefLabel
Mamede de Carvalho
@ast
Mamede de Carvalho
@en
Mamede de Carvalho
@es
Mamede de Carvalho
@nl
Mamede de Carvalho
@sl
P214
P106
P1153
7101893769
P1416
P214
P31
P496
0000-0001-7556-0158
P7859
viaf-98716596